Mesoblast has already stated that it wants to partner for all it’s blockbuster indications that require a lot of people on the ground for distribution, sales, etc.
GVHD it can handle itself.
CHF; COVID and CBP are almost certain going to involve partners. A performance based deal can be struck in advance of trial results. The issue right now is $’s to ramp up manufacturing. Lonza can do with massive amounts of money paid upfront.
Otherwise the company could do a CR, but highly unlikely in my opinion. In last press article BIO world the CEO Itescu said he is already in partnering discussions.
You wanna play with FIRE?, page-32
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |